Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Food Effect of Vapendavir in Healthy and COPD Participants
NCT05962645Phase 1Completed
- Sponsor
- Altesa BioSciences
- Start
- May 2023
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of Vapendavir in human rhinovirus infection and enterovirus infection (2 arms), sponsored by Altesa BioSciences. Primary endpoint: Pharmacokinetic Analyses at 3 weeks. Started May 2023; status: completed.
02
Drugs
Vapendavir
03
Conditions
human rhinovirus infectionenterovirus infection
Beyond the preview
Go deeper on NCT05962645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05962645.